Short-term recombinant human growth hormone administration improves respiratory function in abstinent anabolic-androgenic steroid users.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

To determine whether 6 days recombinant human growth hormone (rhGH) administration, in an abstinent anabolic-androgenic steroid (AAS) using group had any respiratory, endurance exercise and biochemical effects compared with an abstinent AAS control group.

Who Took Part

PubMed tags the participants as men only.

Respiratory measurements examined, were forced expiratory volume in one second, forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure.

How the Study Was Run

The researchers set it up as a randomized and single-blind study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

In this single-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study one party knew the assignments and the other did not.

Anthropometry, respiratory muscle function and endurance exercise were investigated.

Endurance exercise was assessed by measuring peak oxygen uptake (VO(2)peak).

Biochemical analysis included; haemoglobin, packed cell volume, glucose, sodium, urea, creatinine, total protein, albumin, testosterone and insulin like growth factor-I (IGF-I).

What Was Measured

The subject headings attached to it are Doping in Sports, Human Growth Hormone, Patient Compliance, Physical Endurance, Recombinant Proteins, Respiratory Physiological Phenomena and Substance Withdrawal Syndrome.

What This Means in Plain Language

The paper is a randomized and single-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 3 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.